Top 10 Companies in the (R)-Methyl-2-Amino-4-pentenoate Hydrochloride (CAS 217440-34-1) Market (2026): Market Leaders Powering Global Chemistry

MARKET INSIGHTS

Global (R)-Methyl-2-Amino-4-pentenoate Hydrochloride (CAS 217440-34-1) market size was valued at USD 18.4 million in 2025. The market is projected to grow from USD 19.7 million in 2026 to USD 34.2 million by 2034, exhibiting a CAGR of 7.1% during the forecast period.

(R)-Methyl-2-Amino-4-pentenoate Hydrochloride is a chiral amino acid derivative and a protected form of (R)-2-amino-4-pentenoic acid, commonly utilized as a key building block in asymmetric synthesis and pharmaceutical research. Its defined stereochemistry makes it particularly valuable in the preparation of enantiomerically pure compounds, including peptide analogs, enzyme inhibitors, and active pharmaceutical ingredients (APIs). The compound finds application across medicinal chemistry, agrochemical research, and fine chemical manufacturing.

The market is witnessing steady expansion driven by the growing demand for high-purity chiral intermediates in drug discovery and development pipelines, particularly as the pharmaceutical industry increasingly prioritizes stereochemically precise molecules. Furthermore, advancements in peptide-based therapeutics and the broader expansion of contract research and manufacturing organizations (CROs and CMOs) globally continue to support demand for specialized amino acid derivatives such as this compound.

(R)-Methyl-2-Amino-4-pentenoate Hydrochloride (CAS 217440-34-1) Market – View in Detailed Research Report

🔟 1. Merck KGaA (Germany)

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical Grade (R)-Methyl-2-Amino-4-pentenoate Hydrochloride, catalog and custom synthesis

Merck KGaA, through its Sigma‑Aldrich division, has been a pillar in chiral intermediates for decades. Their GMP‑certified facilities produce the hydrochloride salt with >99% ee, meeting stringent FDA and EMA requirements. The company’s advanced enzymatic resolution processes enable scalable production, supporting large‑scale peptide therapeutics and antibody‑drug conjugates.

Sustainability & Growth Initiatives:

• Investment in biocatalytic synthesis to reduce solvent use by 30%
• Partnerships with leading CROs to deliver on‑demand kilogram scale batches
• Expansion of onshore production in North America to mitigate supply chain risks

9️⃣ 2. Tokyo Chemical Industry Co., Ltd. (TCI) (Japan)

Headquarters: Tokyo, Japan
Key Offering: High‑purity (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for peptide synthesis and fine chemical applications

TCI leverages its expertise in chiral catalysis to deliver >99% ee intermediates with robust supply chain integration. Their ISO‑9001 and GMP‑certified plants ensure consistent quality for pharmaceutical and agrochemical markets.

Sustainability & Growth Initiatives:

• Adoption of green chemistry protocols, reducing hazardous solvent usage by 25%
• Strategic alliances with European CROs to accelerate clinical pipeline development
• Investment in continuous‑flow synthesis platforms for scalable production

8️⃣ 3. Thermo Fisher Scientific Inc. (USA)

Headquarters: Waltham, Massachusetts, USA
Key Offering: Research‑grade and pharmaceutical‑grade (R)-Methyl-2-Amino-4-pentenoate Hydrochloride, catalog and on‑demand services

Thermo Fisher’s Alfa Aesar division supplies high‑purity building blocks to academic and industrial labs worldwide. Their global distribution network ensures rapid delivery and support for time‑critical projects.

Sustainability & Growth Initiatives:

• Implementation of waste‑reduction programs in synthesis facilities
• Collaboration with biotech firms to develop custom linker chemistries for ADCs
• Expansion of digital order‑to‑delivery platforms for streamlined procurement

7️⃣ 4. Biosynth AG (Switzerland)

Headquarters: Lenzburg, Switzerland
Key Offering: On‑demand synthesis of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for pharmaceutical and agrochemical clients

Biosynth’s proprietary synthesis routes combine enzymatic resolution with asymmetric catalysis, achieving high enantiomeric excess while maintaining cost efficiency.

Sustainability & Growth Initiatives:

• Investment in biocatalytic processes to lower CO₂ footprint
• Partnerships with European pharma to support green chemistry initiatives
• Expansion of production capacity in the EU to meet growing demand

6️⃣ 5. Enamine Ltd. (Ukraine)

Headquarters: Kyiv, Ukraine
Key Offering: Catalog and custom synthesis of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for research and industrial use

Enamine’s flexible manufacturing platform enables rapid scale‑up, catering to both academic labs and large‑scale pharmaceutical projects.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources in production facilities
• Collaboration with CROs for continuous‑flow synthesis projects
• Development of cost‑effective synthetic routes to lower unit price

5️⃣ 6. Combi-Blocks Inc. (USA)

Headquarters: San Diego, California, USA
Key Offering: Custom synthesis and library building of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for peptide and small‑molecule research

Combi‑Blocks specializes in rapid, high‑throughput synthesis, providing researchers with tailored building blocks for medicinal chemistry and chemical biology.

Sustainability & Growth Initiatives:

• Implementation of green solvent alternatives in synthesis workflows
• Strategic partnerships with biotech firms to develop novel therapeutic scaffolds
• Expansion of digital ordering platform for instant quotes and delivery tracking

4️⃣ 7. Capot Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Production of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for domestic and export markets

Capot’s large‑scale manufacturing capabilities allow competitive pricing while maintaining high purity standards for pharmaceutical intermediates.

Sustainability & Growth Initiatives:

• Investment in energy‑efficient reactors to reduce operational costs
• Collaboration with Chinese CROs to support local drug discovery initiatives
• Adoption of ISO‑14001 environmental management systems

3️⃣ 8. Hairui Chemicals Co., Ltd. (China)

Headquarters: Guangzhou, China
Key Offering: High‑purity (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for pharmaceutical and agrochemical applications

Hairui focuses on scalable production with strict quality controls, catering to both domestic and international customers.

Sustainability & Growth Initiatives:

• Implementation of waste‑recycling programs in synthesis lines
• Partnerships with EU manufacturers to adopt greener synthesis routes
• Expansion of production capacity to meet growing global demand

2️⃣ 9. Finetech Industry Limited (China)

Headquarters: Shenzhen, China
Key Offering: Custom synthesis and bulk production of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for pharma and research sectors

Finetech’s state‑of‑the‑art facilities deliver high‑purity intermediates with rapid turnaround times.

Sustainability & Growth Initiatives:

• Adoption of green chemistry principles to minimize solvent usage
• Collaboration with Chinese CROs to support early‑stage drug development
• Investment in digital twin technology for process optimization

1️⃣ 10. Capot Chemical Co., Ltd. (China)

Headquarters: Shanghai, China
Key Offering: Large‑scale production of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride for pharmaceutical intermediates

Capot’s extensive production network and cost efficiencies position it as a key supplier for global pharma companies seeking high‑purity chiral building blocks.

Sustainability & Growth Initiatives:

• Implementation of renewable energy sources in manufacturing plants
• Strategic alliances with European pharma to deliver on‑demand services
• Continuous improvement of synthesis processes to reduce waste and cost

Download FREE Sample Report: (R)-Methyl-2-Amino-4-pentenoate Hydrochloride (CAS 217440-34-1) Market – View in Detailed Research Report

Get Full Report Here: (R)-Methyl-2-Amino-4-pentenoate Hydrochloride (CAS 217440-34-1) Market – View in Detailed Research Report

🌍 Outlook: The Future of (R)-Methyl-2-Amino-4-pentenoate Hydrochloride Market

The market is poised for sustained growth as the pharmaceutical sector continues to prioritize chiral purity and as new therapeutic modalities such as PROTACs, ADCs, and cyclic peptides emerge. Onshore manufacturing trends in North America and Europe, coupled with strategic collaborations between fine‑chemical suppliers and CROs, are expected to drive higher volumes and tighter lead times.

📈 Key Trends Shaping the Market:

• Rapid expansion of targeted protein‑degrader and antibody‑drug conjugate pipelines
• Increased adoption of green chemistry and biocatalytic synthesis to lower environmental impact
• Growing demand for on‑demand and kilogram‑scale production from CROs and CMOs
• Shift toward digital twins and process optimization to boost yields and reduce cost per gram